Excited to announce results of our #ADDapt trial After 6 years and the help of 154 people with #CrohnsDisease we prove that restricting #emulsifiers improves disease Award winning presentation from Aaron Bancil at #ECCO25 Excited for next steps to help people with Crohns

Our RCT now in Gastroenterology : Pts with #Crohn in remission, who recieved treat-to-target Tx guided by #capsule endoscopy inflammatory assessment, had a significantly lower flare risk over 24m compared to pts continuing standard care Helmsley Charitable Trust gastrojournal.org/article/S0016-…

The impact of setons on perianal fistula outcomes is unclear. After controlling for confounding, setons were not associated with improved fistula outcomes in patients treated with anti-TNF therapy. Read the full paper via bit.ly/4iCZzHW #GItwitter #IBD #fistula

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn’s Disease: Results from the Phase 3 GRAVITI Study - Gastroenterology gastrojournal.org/article/S0016-…

#CGH4ALL Intestinal✂️in Crohn's disease is usually followed by recurrence of🔥in neo-TI. Authors used this as an opportunity to study the role of 🦠🧬 in predicting the recurrence of🔥. doi.org/10.1016/j.cgh.… Report by Nishant Aggarwal, MD Williams Turpin Joanne Stempak

Published CGH 📖 ✅ AGA Clinical Practice Update on Sclerosing Mesenteritis Very useful for every #gastroenterologist cghjournal.org/article/S1542-… American Gastroenterological Association (AGA) #GITwitter #MedTwitter

Number of colonoscopies needed to diagnose cancer based on symptom ‼️ 📸: thieme-connect.de/products/ejour…

Fantastic summary of the nutrition and diet data presented at #ECCO2025 by Nutritional Therapy for IBD So much important work being done by a diverse range of experts to help people with #IBD Thanks for highlighting our ADDapt trial with Aaron Bancil nutritionaltherapyforibd.org/news/ecco25-ke…

There are several important data in this study N=145,300 ❗️Age (mean) 55 1⃣ ASCVD (ischemic cardiovascular, cerebrovascular, or peripheral vascular event) 15% ABT (advanced therapy) 21.2% non-ABT❗️❗️❗️ 2⃣ Within one year ASCVD 8.3% vs. 11.9% ABT vs non-ABT The risk of

Global evolution of inflammatory bowel disease across epidemiologic stages | ⁦nature⁩ ⁦⁦Gil Kaplan MD MPH⁩ nature.com/articles/s4158…

Join us ! Open #Postdoc position in my lab (Paris, France), to work on the Role of the Gut #microbiota in Host Cells Energy Metabolism in Health and #IBD see details here 🔽🔽🔽🔽 euraxess.ec.europa.eu/jobs/361342 please RT

👇👇👇 nature.com/articles/s4157…